• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ROS1 Gene Record

  • Summary
  • Interactions
  • Claims
  • ROS1 6098 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    6098
    ROS PROTO-ONCOGENE 1, RECEPTOR TYROSINE KINASE
    ROS1
    MCF3
    ROS
    c-ros-1
    165020
    10261
    ENSG00000047936
    OTTHUMG00000016188
    4941
    P08922
    ROS1_HUMAN
    PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS PRECURSOR (EC 2.7.1.112) (C-ROS-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P08922]
    PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS
    PA34633
    Reactive oxygen species
    T20796
    Proto-oncogene c-Ros
    T69128

    Gene Info:

    CancerCommons Reported Gene Name ALK, ROS
    Initial Gene Query ROS
    Counted Citations from 1950-2000 4377
    Human Readable Name DRUGGABLE GENOME
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Interpro Acc IPR001245
    Uniprot Status Swiss-Prot
    Human Readable Name KINASE
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Domain
    Gene Biotype PROTEIN_CODING
    (23 More Sources)

    Gene Categories: Category Details

    KINASE
    TYROSINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME
    TRANSCRIPTION FACTOR

    Publications:

    Katayama et al., 2015, Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer., Clin. Cancer Res.
    Awad et al., 2013, Acquired resistance to crizotinib from a mutation in CD74-ROS1., N. Engl. J. Med.
    Davare et al., 2015, Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors., Proc. Natl. Acad. Sci. U.S.A.
    Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Zou et al., 2015, PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations., Proc. Natl. Acad. Sci. U.S.A.
    Mazières et al., 2015, Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort., J. Clin. Oncol.
    Shaw et al., 2014, Crizotinib in ROS1-rearranged non-small-cell lung cancer., N. Engl. J. Med.
    Lovly et al., 2014, Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions., Cancer Discov
    Wu YL et al., 2018, Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer., J Clin Oncol
    Le et al., 2015, Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling., Clin Lung Cancer
    Bergethon et al., 2012, ROS1 rearrangements define a unique molecular class of lung cancers., J. Clin. Oncol.
    Gainor JF et al., 2017, Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer., JCO Precis Oncol
    Shaw AT et al., 2019, Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001., Ann Oncol
    Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
    Chong et al., 2017, Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer., Clin. Cancer Res.
    Drilon et al., 2016, A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer., Clin. Cancer Res.
    Davare MA et al., 2018, Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma., Clin Cancer Res
    Facchinetti F et al., 2016, Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers., Clin Cancer Res
    Drilon et al., 2017, Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)., Cancer Discov
    Liu D et al., 2018, Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumors., Ther Clin Risk Manag
    Rolfo C et al., 2015, Entrectinib: a potent new TRK, ROS1, and ALK inhibitor., Expert Opin Investig Drugs
    Pacenta HL et al., 2018, Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma., Drug Des Devel Ther
    Ardini et al., 2016, Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications., Mol. Cancer Ther.
    Lim et al., 2017, Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement., J. Clin. Oncol.
    Zhang et al., 2016, The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models., Clin. Cancer Res.
    Drilon A et al., 2018, Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations., Cancer Discov
  • LORLATINIB   ROS1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    30171048 25733882 27401242


    Sources:
    JAX-CKB CIViC PharmGKB TTD FDA

  • CRIZOTINIB   ROS1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Clinical Status case report
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    25351743 23724914 26372962 25688157 25733882 25667280 25264305 24875859 29596029 25922291 22215748 29333528 30980071


    Sources:
    TALC MyCancerGenome JAX-CKB DoCM CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

  • REPOTRECTINIB   ROS1

    Interaction Score: 2.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    30093503


    Sources:
    CIViC

  • PROCYSTEINE   ROS1

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BRIGATINIB   ROS1

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26372962


    Sources:
    CIViC

  • TAFENOQUINE   ROS1

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CABOZANTINIB   ROS1

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Clinical Study
    Response Type predicted – sensitive

    PMIDs:
    27370605 26372962 25351743 26673800


    Sources:
    JAX-CKB CIViC

  • CERITINIB   ROS1

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    26372962 28520527


    Sources:
    JAX-CKB CIViC

  • CHEMBL3397300   ROS1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    27780853


    Sources:
    JAX-CKB

  • FORETINIB   ROS1

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25688157 26372962


    Sources:
    CIViC

  • ASP-3026   ROS1

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Lung

    PMIDs:
    None found


    Sources:
    CancerCommons

  • NEFLAMAPIMOD   ROS1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ENTRECTINIB   ROS1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type pancreatic cancer
    Response Type predicted – sensitive
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    28183697 30050303 26457764 30425456 26939704


    Sources:
    JAX-CKB CIViC PharmGKB FDA

  • MLN-8054   ROS1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SB-202190   ROS1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AST-487   ROS1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HESPERADIN   ROS1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19035792


    Sources:
    DTC

  • ALISERTIB   ROS1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SNS-314   ROS1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OSI-632   ROS1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • JNJ-7706621   ROS1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TOZASERTIB   ROS1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • R-406   ROS1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RG-1530   ROS1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYC-116   ROS1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PF-00562271   ROS1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILORASERTIB   ROS1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CENISERTIB   ROS1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000047936

    • Version: 101_38

    Alternate Names:
    ROS1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • BaderLabGenes: ROS1

    • Version: February-2014

    Alternate Names:
    6098 Entrez Gene ID

    Gene Info:
    Initial Gene Query ROS
    Counted Citations from 1950-2000 4377

    Gene Categories:
    KINASE

    Publications:

  • HopkinsGroom: P08922

    • Version: 11-September-2012

    Alternate Names:
    6098 Entrez Gene Id
    ROS1 Uniprot Gene Name
    ENSG00000047936 Ensembl Gene Id

    Gene Info:
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Interpro Acc IPR001245
    Uniprot Status Swiss-Prot

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000047936

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000047936 Ensembl Gene Id
    ROS1 Display Id
    PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS PRECURSOR (EC 2.7.1.112) (C-ROS-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P08922] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • CancerCommons: ROS1

    • Version: 25-July-2013

    Alternate Names:
    6098 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name ALK, ROS

    Publications:

  • JAX-CKB: ROS1

    • Version: 27-September-2017

    Alternate Names:
    6098 CKB Entrez Id
    ROS1 CKB Gene Synonym
    c-ros-1 CKB Gene Synonym

    Gene Info:

    Publications:
    Rho et al., 2014, MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation., Cancer Res.
    Drilon et al., 2017, Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)., Cancer Discov
    Chong et al., 2017, Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer., Clin. Cancer Res.

  • CIViC: ROS1

    • Version: 14-September-2020

    Alternate Names:
    6098 Entrez Gene ID
    4941 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE, CLINICALLY ACTIONABLE

    Publications:
    Wu YL et al., 2018, Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer., J Clin Oncol
    Awad et al., 2013, Acquired resistance to crizotinib from a mutation in CD74-ROS1., N. Engl. J. Med.
    Shaw et al., 2014, Crizotinib in ROS1-rearranged non-small-cell lung cancer., N. Engl. J. Med.

  • DoCM: ROS1

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Awad et al., 2013, Acquired resistance to crizotinib from a mutation in CD74-ROS1., N. Engl. J. Med.
    Zou et al., 2015, PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations., Proc. Natl. Acad. Sci. U.S.A.
    Katayama et al., 2015, Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer., Clin. Cancer Res.

  • DTC: ROS1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.

  • HingoraniCasas: ENSG00000047936

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000047936 Gene Symbol
    ROS1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • MyCancerGenome: ROS1

    • Version: 20-Jun-2017

    Alternate Names:
    6098 Entrez Gene Id
    ROS1 MyCancerGenome Gene Symbol
    ROS1 MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • TALC: ROS1

    • Version: 12-May-2016

    Alternate Names:
    ROS1 Gene Symbol

    Gene Info:

    Publications:

  • OncoKB: ROS1

    • Version: 23-July-2020

    Alternate Names:
    6098 OncoKB Entrez Id
    MCF3 OncoKB Gene Synonym
    ROS OncoKB Gene Synonym

    Gene Info:

    Publications:

  • PharmGKB: ROS1

    • Version: 18-August-2020

    Alternate Names:
    PA34633 PharmGKB ID

    Gene Info:

    Publications:

  • HumanProteinAtlas: ROS1

    • Version: 19.3

    Alternate Names:
    ENSG00000047936 Ensembl Gene ID
    c-ros-1 Human Protein Atlas Gene Synonym
    MCF3 Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • GO: ROS1

    • Version: 01-February-2022

    Alternate Names:
    MCF3 GO Gene Synonym
    ROS GO Gene Synonym

    Gene Info:

    Gene Categories:
    TYROSINE KINASE

    Publications:

  • Tempus: ROS1

    • Version: 11-November-2018

    Alternate Names:
    ROS1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: ROS1

    • Version: 27-Jun-2013

    Alternate Names:
    6098 Gene ID
    MCF3 dGene Synonym
    ROS dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • TTD: Reactive oxygen species

    • Version: 2020.06.01

    Alternate Names:
    ROS TTD Gene Abbreviation
    T20796 TTD Target ID

    Gene Info:

    Publications:

  • TTD: Proto-oncogene c-Ros

    • Version: 2020.06.01

    Alternate Names:
    ROS1 TTD Gene Abbreviation
    T69128 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: ROS1

    • Version: 01-February-2022

    Alternate Names:
    Proto-oncogene tyrosine-protein kinase ROS Gene Name
    P08922 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE, TRANSCRIPTION FACTOR

    Publications:

  • MyCancerGenomeClinicalTrial: ROS1

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: ROS1

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: ROS1

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: ROS1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FDA: ROS1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

  • Oncomine: ROS1

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21